











































Prostaglandin-cytokine crosstalk in chronic inflammation
Citation for published version:
Yao, C & Narumiya, S 2018, 'Prostaglandin-cytokine crosstalk in chronic inflammation', British Journal of
Pharmacology. https://doi.org/10.1111/bph.14530
Digital Object Identifier (DOI):
10.1111/bph.14530
Link:




British Journal of Pharmacology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/bph.14530 
 
This article is protected by copyright. All rights reserved. 









Centre for Inflammation Research, Queen's Medical Research Institute, The University of 
Edinburgh, Edinburgh EH16 4TJ, UK 
 
2
Alliance Laboratory for Advanced Medical Research and Department of Drug Discovery 





Correspondence Dr C Yao, Medical Research Council (MRC) Centre for Inflammation 
Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh 
EH16 4TJ, UK. E-mail: Chengcan.Yao@ed.ac.uk; and Professor S Narumiya, Medical 
Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. 







This article is protected by copyright. All rights reserved. 
Abstract 
Chronic inflammation underlies various debilitating disorders including autoimmune, 
neurodegenerative, vascular and metabolic diseases as well as cancer, where aberrant 
activation of the innate and acquired immune systems is frequently seen. Since non-steroidal 
anti-inflammatory drugs (NSAIDs) exert their effects by inhibiting cyclooxygenase (COX) 
and suppressing prostaglandin (PG) biosynthesis, PGs have been traditionally thought to 
function mostly as mediators of acute inflammation. However, an inducible COX isoform, 
COX-2, is often highly expressed in tissues of the chronic disorders, suggesting a yet 
unidentified role of PGs in chronic inflammation. Recent studies have shown that in addition 
to their short-lived actions in acute inflammation, PGs crosstalk with cytokines and amplify 
the cytokine actions on various types of inflammatory cells, and drive pathogenic conversion 
of these cells by critically regulating their gene expression. One mode of such PG-mediated 
amplification is to induce expression of relevant cytokine receptors, which is typically 
observed in Th1 cell differentiation and Th17 cell expansion, events leading to chronic 
immune inflammation. Another mode of amplification is cooperation of PGs with cytokines 
at the transcription level. Typically, PGs and cytokines synergistically activate NF-B to 
induce expression of inflammation-related genes, one being COX-2 itself, which makes PG-
mediated positive feedback loops. This signalling consequently enhances expression of 
various NF-kB induced genes including chemokines to macrophages and neutrophils, which 
enables sustained infiltration of these cells and further amplifies chronic inflammation. In 
addition, PGs are also involved in tissue remodelling such as fibrosis and angiogenesis. In 
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Abbreviations 
 
APC, antigen-presenting cell; AS, ankylosing spondylitis; cAMP, cyclic adenosine 
monophosphate; CBP, CREB binding protein; CHS, contact hypersensitivity; COX, 
cyclooxygenase; CREB, cAMP response element binding protein; CRTC2, CREB Regulated 
Transcription Coactivator 2; CRTH2, chemoattractant receptor-homologous molecule 
expressed on Th2 cells; DAMP, damage-associated molecular pattern; DC, dendritic cells; 
DP, PGD receptor; EAE, experimental autoimmune encephalomyelitis; EP, PGE receptor; 
FLS, fibroblast-like synoviocyte; FP, PGF receptor; GC, germinal center; GWAS, genome-
wide association study; IA, intracranial aneurysm; IBD, inflammatory bowel disease; IFN, 
interferon; IL, interleukin; IL-1R, IL-1 receptor; IL-12Rβ2, IL-12 receptor β2 chain; IL-23R, 
IL-23 receptor; ILC, innate lymphoid cell; ILC1, type 1 ILC; ILC2, type 2 ILC; ILC3, type 3 
ILC; IP, PGI receptor; KO, knockout; LPS, lipopolysaccharides; mPGES1, microsomal 
prostaglandin E synthase-1; MS, multiple sclerosis; NERD, NSAID-induced exacerbated 
respiratory disease; NF-κB, nuclear factor-κB; NSAID, non-steroidal anti-inflammatory drug; 
OVA, ovalbumin; PAMP, pathogen-associated molecular pattern; PG, prostaglandin; PI3K, 
phosphatidylinositol-3 kinase; PKA, protein kinase A; PMN, polymorphonuclear leukocyte; 
RA, rheumatoid arthritis; TARC, thymus and activation-regulated chemokine; TCR, T cell 
receptor; TGF-β, transforming growth factor β; Th cell, helper T cell; Th1 cell, type 1 Th cell; 
Th17 cell, type 17 Th cell; Th2 cell, type 2 Th cell; TLR, toll-like receptor; TP, TXA receptor; 
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Introduction 
Upon invasion of foreign pathogens or tissue damage, the innate immune system is 
immediately activated in response to molecules bearing pathogen-associated molecular 
patterns (PAMPs) and damage-associated molecular patterns (DAMPs), recruits granulocytes 
to the injured tissue to clear pathogens, produces inflammatory mediators including 
proinflammatory cytokines such as tumor necrosis factor (TNF)-, interleukin (IL)-1 and 
IL-6 and lipid mediators such as prostaglandins (PGs) and leukotrienes (LTs), and evokes an 
acute inflammatory process (hours to days) to clear the pathogens and damaged tissues. 
Acute inflammation is resolved and the tissue is repaired when PAMPs, DAMPs, pathogens 
and damaged tissues are cleared, granulocyte recruitment is ceased with down-regulation and 
scavenging of chemokines, and recruited granulocytes are subsequently cleared by 
efferocytosis. However, inflammation often becomes chronic (weeks to months to years), 
which underlie various chronic disorders such as autoimmune, neurodegenerative, vascular 
and metabolic diseases and cancer. Recent studies in various experimental systems have 
begun to unravel possible mechanisms how inflammation is sustained and becomes chronic. 
They include generation of positive feedback mechanisms to self-amplify inflammatory 
responses or suppression of negative feedback mechanisms to prevent resolution, leading to 
recruitment, activation, phenotypic transformation and synergistic interaction of various types 
of cells and to sustain proinflammatory cytokine signalling at inflammatory sites. 
 
Prostaglandins (PGs) including PGD2, PGE2, PGF, PGI2 and thromboxane A2 (TXA2) are 
produced in most tissue and cells either constitutively by physiological stimuli or in response 
to noxious stimuli.  In either case, C20-unsaturated fatty acids such as arachidonic acid are 
released from phospholipids in cell membrane and converted into PGH2 by cyclooxygenases 
(COXs including COX1 and COX2). PGH2 is then converted into each PG by respective PG 
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synthases (Figure 1A). PGs exert their actions through a family of eight types and subtypes 
of G protein-coupled receptors (GPCRs), PGD receptor (originally named DP and now called 
DP1), EP1, EP2, EP3 and EP4 subtypes of PGE receptor, PGF receptor (FP), PGI receptor 
(IP) and TXA receptor (TP), and another PGD receptor in a different GPCR family, 
originally named CRTH2 and now called DP2. These PG receptors activate distinct 
downstream signalling pathways and thus have divergent, sometimes additive and other times 
opposing, functions in various physiological and pathological processes. For example, while 
EP2, EP4, DP1 and IP activate cAMP signalling, EP3 and DP2 inhibit cAMP signalling. EP1, 
FP and TP mainly activate the PKC and Ca
2+
 pathways. TP and EP3 also activate the small 
G-protein Rho; EP2 and EP4 can also activate PI3K and -arrestin pathways (Figure 1B). 
Aspirin-like non-steroidal anti-inflammatory, anti-pyretic and analgesic drugs (NSAIDs) 
exert their actions by targeting COX and inhibiting PG biosynthesis. PAMPs/DAMPs such as 
lipopolysaccharide (LPS) and proinflammatory cytokines such as IL-1 and TNF- induce 
expression of inducible isoforms of COX and PGE synthase, COX-2 and microsomal PGE 
synthase 1 (mPGES1), respectively (Díaz-Muñoz et al., 2010). Therefore, PGs have been 
traditionally thought as inflammatory mediators linking innate immunity to acute 
inflammation. Indeed, studies using genetically modified mice deficient in each PG receptor 
identified types of PG and their receptors involved in each of acute inflammatory responses 
(Narumiya and Furuyashiki, 2011). However, expression of COX-2 and mPGES1 is not 
limited to the sites of acute inflammation but widely seen in tissues of chronic inflammation 
such as the joints of RA patients, the spinal cord of MS patients, the colon of IBD patients, 
the cerebral arterial wall of cerebral aneurysm patients, and tumors and their 
microenvironment of many cancers (Ricciotti and FitzGerald, 2011; Wang and DuBois, 
2018). These findings suggest that in addition to their actions in acute inflammation, PGs also 
play important roles in many chronic inflammatory diseases. Recent studies using PG 
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receptor knockout (KO) mice and PG receptor-type selective agonists and antagonists in 
various animal models of chronic diseases have revealed that PGs intimately crosstalk with 
cytokines, drive pathogenic conversion, recruit and activate inflammatory cells and contribute 
to chronic inflammation through various mechanisms. Furthermore, genome-wide association 
studies (GWASs) and gene signature analyses of disease tissues of patients strongly suggest 
relevance of these experimental findings to chronic inflammation in humans. Here we review 
these findings and discuss therapeutic potential of PG-related drugs in chronic human 
diseases. 
 
1. PG-cytokine crosstalk in immune and allergic inflammation 
Acute inflammation often becomes chronic, when acquired immunity is raised against 
pathological antigens generated at inflammatory sites and causes immune inflammation. 
Antigens generated at inflammatory sites are taken up by antigen-presenting cells (APCs) 
such as dendritic cells (DCs) and macrophages, which are activated upon this uptake, migrate 
to draining lymph nodes, and present the antigens to T lymphocytes to trigger the adaptive 
immune system. Activated APCs also produce various cytokines, which prime antigen-
activated T cells to differentiate into specific subsets of helper T (Th) cells that produce the 
subset-specific cytokines and trigger inflammation. Type 1 subset of Th cells (Th1) produce 
interferon (IFN)-γ, Th2 cells produce type 2 cytokines including IL-4, IL-5 and IL-13, and 
Th17 cells produce IL-17A, IL-17F and IL-22. The generation of Th1, Th2 and Th17 cells is 
primarily to expel invaded pathogens, but activation and differentiation of these T cells, if not 
properly controlled, can trigger immune diseases (Zhu et al., 2010). Th1 and Th17 cells play 
critical roles in development of autoimmune inflammatory diseases such as multiple sclerosis 
(MS), inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and psoriasis. Indeed, 
accumulation of Th1 and Th17 cells and elevation of their signature cytokines have been 
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found in the brain, synovial fluid, gut and skin of patients with MS, RA, Crohn’s disease and 
psoriasis, respectively (Zhu et al., 2010). Further, administration of antibodies targeting to 
cytokines they produce has shown clinical efficacy in some of these diseases (Zhu et al., 
2010). On the other hand, Th2 cells are involved in allergic inflammation such as atopic 
dermatitis and asthma. As described below, a number of studies now suggest that PGs, 
particularly PGE2, contributes critically to immune inflammation by facilitating 
differentiation and pathogenic conversion of Th1 and Th17 cells, and that various PGs are 
also involved in different aspects of Th2-mediated allergic inflammation. Studies have also 
appeared to indicate that PGs are involved in modulation of innate lymphoid cells (ILCs), a 
class of lymphoid cells mirroring T cells but not expressing T cell receptor (TCR). Figure 2 
summarizes PG actions on different inflammatory responses driven by different subsets of T 
and ILC cells which will be discussed in detail below.  
 
1.1. PG signalling in immune inflammation mediated by Th1 and Th17 cells 
1.1.1. PGE2-EP2/EP4 signalling in Th1 differentiation 
Differentiation of Th1 cells is driven by two critical cytokines, IL-12 and IFN-γ. Upon TCR 
engagement, T cells produce a small amount of IFN-γ that binds to IFN-γ receptor and 
induces a low level of IL-12 receptor β2 chain (IL-12Rβ2), enabling T cell responses to IL-12. 
IL-12-IL-12R interaction then activates transcription factors T-bet and signal transducer and 
activator of transcription 4 (STAT4) and amplifies expression of IL-12Rβ2 as well as 
produces a large amount of IFN-γ for Th1 differentiation (Zhu et al., 2010). PGE2 has been 
believed for long time as an immunosuppressive substance suppressing Th1 cell development 
and function in in vitro studies (Betz and Fox, 1991; Harris et al., 2002). However, recent 
studies indicate that the inhibitory action of PGE2 depends on the extent of TCR stimulation 
conditions as well as co-existing cytokines. Substantial in vitro and in vivo evidence now 
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shows that PGs can act as an immune-activator under numerous conditions. Indeed, under the 
enhanced TCR stimulation, PGE2 facilitated, rather than inhibited, IL-12-primed Th1 cell 
differentiation and this was mediated by EP2 and EP4 receptors through cAMP-PKA 
pathway (Yao et al., 2009). Furthermore, PGE2 promotes Th1 cell differentiation by 
induction of IL-12Rβ2 and IFN-γ receptor α chain (IFN-γR1), thus amplifying the IL-12 and 
IFN-γ signalling pathways (Yao et al., 2013). Mechanistically, PGE2-EP2/EP4-cAMP-PKA 
signalling activates cAMP-response element binding protein (CREB) by CREB 
phosphorylation and its co-factor CREB-regulated transcription co-activator 2 (CRTC2) 
through CRTC2 de-phosphorylation (Screaton et al., 2004), both of which then translocate to 
the nucleus, bind to IL-12Rβ2 and IFN-γR1 gene loci to initiate their transcription (Yao et al., 
2013). These results have thus clearly established that the PGE2-EP2/EP4-cAMP-PKA 
pathway can facilitate Th1 cell development through crosstalk with IL-12 and IFN-γ (Figure 
3A). In addition to PGE2, PGI2 appears to similarly promote Th1 differentiation possibly 
through cAMP-PKA signalling (Nakajima et al., 2010).  
 
1.1.2. PGE2 signalling in T cells and DCs for generation of pathogenic Th17 cells. 
1.1.2.1. PGE2-EP2/EP4 signalling in expansion and pathogenic conversion of Th17 cells 
Th17 cells drive chronic immune inflammation through the pro-inflammatory cytokines they 
produce, e.g., IL-17A, IL-17F, and IL-22 (Stockinger and Omenetti, 2017). Mouse Th17 cells 
are induced from naïve T cells by transforming growth factor β (TGF-β) and IL-6 and then 
expanded and maturated by IL-23. Primarily differentiated Th17 cells express relatively less 
amount of IL-17A and IL-23 receptor (IL-23R) and have less pathogenicity. Once these cells 
are further stimulated by IL-23, they express high levels of IL-23R, produce large amounts of 
IL-17A and other cytokines (such as IL-17F, IL-22, GM-CSF) and become more pathogenic 
(Lee et al., 2012). Human Th17 cells can be induced by IL-23 and IL-1β either with or 
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without TGF-β. Unlike Th1 cells, Th17 cell differentiation by TGF-β and IL-6 is inhibited by 
PGE2, possibly due to down-regulation of TCR signalling and TGF-β signalling. However, 
PGE2 markedly enhances IL-23-stimulated Th17 cell proliferation and production of IL-17 
and IL-22, the action also mediated by EP2 and EP4 through downstream cAMP-PKA 
pathway (Yao et al., 2009). Intriguingly, suppression of endogenous cAMP production by 
deficiency of the stimulatory Gα subunit of the heterotrimeric G protein on T cells down-
regulated Th17 and Th1 cell differentiation (Li et al., 2012). Recently, Lee et al examined 
molecular mechanisms of PGE2-EP2/EP4-mediated amplification of IL-23-induced Th17 
expansion in detail and found that this PGE2 pathway amplifies IL-23-induced IL-23R 
expression by not only further activating signal transducer and activator of transcription 3 
(STAT3) but also activating NF-B and CREB through cAMP (Lee et al., 2018). 
Interestingly, they found that IL-23 induces expression of COX-2 in Th17 cells and inhibition 
of PG synthesis with indomethacin attenuates the IL-23 action, suggesting that IL-23 
mobilizes endogenous Th17 cell-intrinsic PGE2 system to augment its effects. They further 
showed that the cAMP pathway not only enhances IL-23-induced gene expression but also 
induces expression of a variety of genes that are not induced by IL-23 alone and confers more 
pathogenic signature to Th17 cells (Lee et al., 2018). Involvement of CREB and its co-
activator CRTC2 in promoting Th17 cells were also reported by other groups (Wang et al., 
2017; Hernandez et al., 2015). These studies suggested that the promoting action of PGE2 on 
pathogenic Th17 cells is, at least partly, due to direct binding of CREB and CRTC2 to IL-
17A promoter and enhancing its gene transcription (Figure 3B).  
 
The PGE2-EP2/EP4-cAMP signalling pathway also promotes IL-23/IL-1β-stimulated 
expansion and activation of human Th17 cells (Chizzolini et al., 2008; Boniface et al., 2009; 
Napolitani et al., 2009). As seen in mouse T cells, PGE2 signalling not only directly enhances 
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induction of IL-17A gene transcription but induces receptors for the involved cytokines. 
Boniface et al observed up-regulation of expression of IL-23R and IL-1R in PGE2-stimulated 
human Th17 cells and proposed that PGE2 amplifies IL-23-IL-23R and IL-1β-IL-1R 
signalling to optimize IL-17A production. They further reported that of the two EPs, EP2 is 
predominantly responsible for Th17 cytokine production, while EP4 exerts the additional 
effects such as inhibiting IL-10 and IFN- production in Th17 cells (Boniface et al, 2009). 
Consistent with these findings, blockade of transcriptional co-activators of CREB, CREB 
binding protein (CBP) and p300, by the bromodomain CBP30 inhibits IL-17A secretion by 
human Th17 cells (Hammitzsch et al., 2015). Furthermore, a recent study demonstrated that 
EP2 is overexpressed in T cells from MS patients, while its expression in T cells in healthy 
individuals undergoes retinoic acid-related orphan nuclear hormone receptor C-dependent 
silencing, and that simulation of EP2 in the MS patient T cells induces a pathogenic Th17 
phenotype characterized by co-expression of both IL-17A and IFN- (Kofler et al., 2014), 
thus providing clinical relevance of the finding on PGE2-EP2 signalling in mouse Th17 cells. 
Taken together, these studies clearly indicate the important roles for PGE2 in the development 
of pro-inflammatory Th17 cells and, as described later, the pathogenesis of chronic 
inflammation in mouse and human (Figure 3B).  
 
The discrepancy between previous observations on PGE2 suppression of T cell activation, 
proliferation and cytokine production (Harris et al., 2002) and recent findings about PGE2 
facilitation of Th1 and Th17 cell responses (Yao et al., 200; Yao et al., 2013; Lee et al., 2018; 
Chen et al., 2010; Sheibanie et al., 2007a; Chizzolini et al., 2008; Boniface et al., 2009) may 
be caused by multiple factors. One is that different concentrations of PGE2 were used in the 
experiments. In most previous studies with in vitro cell cultures, PGE2 was used at the 
micromolar levels, but actual concentrations of PGE2 in vivo, especially in humans, are 
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usually at nanomolar levels, examples being those in cerebrospinal fluid from MS patients 
(Mattsson et al., 2009) and in joint fluid from RA patients (Hishinuma et al., 1999). PGE2 
was found at similar levels at ng/g wet tissue of rectal mucosa from UC patients (Sharon et al., 
1978) and of colonic mucosa from rat with DSS-induced colitis (Yamashita, 1993). TCR-
dependent T cell activation and function was inhibited by high rather than low (~nM) 
concentrations of PGE2. In contrast, the low, nanomolar concentrations of PGE2 facilitated 
Th1 and Th17 cell responses in both in vitro and in vivo assays (Yao et al., 2009; Yao et al., 
2013; Lee et al., 2018). Another factor may be the different T cell stimulation conditions, e.g., 
the strength of TCR-co-stimulation and the cytokine milieu presented during T cell 
differentiation and expansion (Yao et al., 2013; Lee et al., 2018). Altogether, PGE2 can have 
both pro- and anti-inflammatory effects depending on its local concentrations, the disease 
settings, and also the timing of its action.  
 
1.1.2.2. PGE2-EP2/EP4 signalling in migration, maturation and IL-23 production of DCs 
Involvement of PGs in acquired immunity is not limited to regulation of T cells but also seen 
in APCs. Kabashima et al found that, in response to antigen uptake, migration of Langerhans 
cells to reginal lymph nodes, expression of costimulatory molecules and their ability to 
stimulate T cells were impaired in EP4-deficient mice, suggesting a critical role of PGE2-EP4 
signalling in DC maturation and migration after antigen uptake (Kabashima et al., 2003b). 
PGE2 was also reported to up-regulate OX40L expression on human monocyte-derived DCs, 
which in turn enhanced the OX40-OX40L co-stimulation to enhance human antigen-specific 
T cell proliferation in in vitro T cell-DC cocultures (Krause et al., 2009). PGE2 is further 
involved in IL-23 production by activated DCs. Ganea’s group showed that various toll-like 
receptor (TLR) ligands such as LPS, Poly-I-C, CpG and proteoglycan induce expression of 
IL-23 p19 subunit in DCs, and that PGE2 potently enhances this action via EP2 and EP4 in 
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vitro (Sheibanie et al., 2004; Khayrullina et al., 2008). In the animal model of collagen-
induced arthritis, administration of PGE2 analogue, misoprostol exacerbated joint 
inflammation and this was associated with increased messenger RNA levels of IL-23 p19 and 
other proinflammatory cytokines such as IL-17, IL-6 and IL-1 (Sheibanie et al., 2007a). 
This PGE2 action is exerted by interaction between nuclear factor κB (NF-κB) activated by 
TLR pathway and CREB and C/EBP- activated by the PGE2-EP4-cAMP-PKA and EPAC 
pathways, respectively (Kocieda et al., 2012). The PGE2-mediated enhancement of IL-23 
production was also seen in DCs stimulated with anti-CD40 antibody and, interestingly, the 
treatment with indomethacin or an EP4 antagonist almost completely suppressed IL-23 
production in vitro (Yao et al., 2009), suggesting that DC-intrinsic PGE2 amplifies IL-23 
production through a positive feedback loop. Further study by Ma et al showed that anti-
CD40 antibody stimulation induced two phases of IL-23 gene expression, the first with a 
peak at 1 h and the second lasting up to 36 h, while LPS or TNF- induced only the early 
response of IL-23 gene expression. PGE2 or an EP4 agonist and not an EP2 agonist amplified 
both phases of the anti-CD40 response by tens of folds (Ma et al., 2016). Mechanistic 
analysis revealed that the early phase was mediated by canonical NF-κB signalling and the 
late phase by non-canonical NF-κB signalling and that PGE2-EP4 signalling exhibited 
synergistic action in both signalling (Figure 3C). One pathological implication of the IL-23 
induction by this PGE2 signalling is in cancer. The IL-23 to IL-17 cascade through IL-23 
receptor is also implicated in various human cancers including those of the colon, ovary, lung, 
breast, stomach, skin, liver and head and neck (Wang and Karin, 2015). Qian et al found that 
mice bearing 4T1 breast tumour cells have increased number of Th17 cells not only in 
tumour tissues but also in the spleen and peripheral blood, and that this is due to PGE2 
secreted from tumour, which induces IL-23 in DCs through EP2/EP4 and CREB-dependent 
manner (Qian et al., 2013). In addition, Kabashima et al reported that engagement of TP in T 
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cells with TXA2 produced by DCs resulted in impaired DC-T cell adhesion and inhibited DC-
dependent T cell proliferation in vitro, while TP-deficient or TP-antagonist-treated mice had 
enhanced acquired immune response to foreign antigens in vivo (Kabashima et al., 2003a). A 
further study indicates that TXA2 tonically suppresses interaction of weak CD4+ T cells and 
DCS through TP (Moalli et al., 2014). 
 
1.1.3. PGE2-EP2/EP4 signalling in Th1/Th17-mediated immune inflammation; animal 
models and human relevance 
Given the PGE2-EP2/EP4-mediated facilitation of differentiation of Th1 cells, expansion and 
pathogenic conversion of Th17 cells and IL-23 production by DCs, several studies have 
examined the significance of this signalling in Th1- and Th17-driven immune inflammation 
in various animal models of autoimmune diseases such as MS (Yao et al., 2009; Kihara et al., 
2009; Esaki et al., 2010; Hernandez et al., 2015), IBD (Sheibanie et al., 2007b; Wang et al., 
2017), arthritis (Chen et al., 2010; Monk et al., 2014), allergic lung inflammation (Li et al., 
2011), and atherosclerosis (Kotla et al., 2013), and their relevance to human autoimmune 
diseases. For example, blockade of PGE2-EP4 signalling by pharmacological (e.g. COX 
inhibitors, EP4 antagonists) or genetic approaches (e.g. knockouts of mPGES1 or EP4 genes) 
suppressed myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune 
encephalomyelitis (EAE) and reduced Th1 and Th17 cell development, and this suppressing 
effects were further enhanced by co-inhibition of EP2 (Yao et al., 2009; Esaki et al., 2010; 
Kihara et al., 2009). Pharmacological antagonism of EP4 also attenuated collagen-induced 
arthritis progression with concomitant inhibition of IFN-γ and IL-17A production (Chen et al., 
2010; Sheibanie et al., 2007a). While conditional deletion of EP4 in T cells ameliorated T 
cell-mediated chronic colitis accompanied with reduction of Th1 accumulation in colon (Yao 
et al., 2013), administration of PGE2 or misoprostol, an EP3/EP4 agonist, augmented 2,4,6-
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trinitrobenzene sulfonic acid-induced colitis with increase in IL-17 and IL-23 levels in 
inflamed colon (Sheibanie et al., 2007b). Recently, Lee et al showed that T cell-specific 
deletion of EP2 and EP4 in combination suppressed psoriasis-like skin inflammation induced 







 T cell accuulation in the lesion, suggesting the critical role of T cell-intrinsic 
EP2/EP4 signalling in development of immune inflammation (Lee et al., 2018). Moreover, 
deletion of Gs or CREB in T cells similarly reduced Th17-induced chronic colitis and EAE 
(Li et al., 2012; Wang et al., 2017). Although PGE2 essentially protects acute epithelial injury 
(Kabashima et al., 2002; Duffin et al., 2016), these studies together suggested the detrimental 
action of PGE2 signalling in Th17 cells in the gut. Similar to PGE2, activation of PGI2-IP 
signalling has also been reported to foster Th17 cell responses and exacerbates chronic 
inflammation mediated by this type of cells in EAE and enhances activation of Th17 cells 
from systemic sclerosis patients (Zhou et al., 2012; Truchetet et al., 2012). Therefore, 
blockade of PGE2 or PGI2 production by inhibiting COX, mPGES1 or receptors by small 
molecular inhibitors would be effective treatment in progression of autoimmune diseases.  
 
Clinical relevance of these findings to human autoimmune diseases is indicated by 
experimental findings that patients with autoimmune inflammatory diseases like IBD and MS 
had elevated levels of PGE2 in serum and the site of inflammation, e.g., the cerebrospinal 
fluid for MS (Mattsson et al., 2009; Prüss et al., 2013) and genetic findings from recent 
GWAS studies, which have identified Ptger4 (EP4) as a susceptible locus in a number of 
autoimmune diseases including inflammatory bowel disease (IBD) (Glas et al., 2012), 
multiple sclerosis (MS) (International Multiple Sclerosis Genetics Consortium et al., 2011), 
ankylosing spondylitis (AS) and allergy (Hinds et al., 2013; Parkes et al., 2013). Numerous 
GWAS studies have suggested that polymorphisms in the 5p13.1 regulatory regions near 
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PTGER4 (e.g., rs9292777, rs7725052, rs77145747, rs6896969 and rs4613763) were 
significantly associated with PTGER4 gene expression and the susceptibility of MS 
(International Multiple Sclerosis Genetics Consortium et al., 2011; De Jager et al., 2009; 
Matesanz et al., 2012). In human IBD, gene polymorphisms in PTGER4 loci (e.g., rs4613763, 
rs16869977, rs10512739, rs6880934 and rs9292777) were similarly associated the 
susceptibility of Crohn’s disease (CD) (Libioulle et al., 2007; Barrett et al., 2008; Kenny et 
al., 2012). Further studies indicated that rs7720838 and rs4495224 were also associated with 
susceptibility to CD and contributed to increased PTGER4 gene expression by enhancing 
binding of NF-kB and XBP1 (Glas et al., 2012) and that the disease behavior in CD patients 
was enhanced if mutant alleles in both rs7720838 and NOD2 were present (Prager et al., 
2014). PGs (e.g., PGE2 and PGI2) also promotes chronic joint inflammation and NSAIDs are 
the first line medications for treating arthritis. Polymorphisms (rs10440635 and rs76523431) 
in PTGER4 loci were associated with increased PTGER4 gene expression in synovial biopsy 
samples from patients with spondyloarthritis but also the susceptibility and severity of AS 
(Evans et al., 2011; Chai et al., 2013). Interestingly, rs12186979 and rs13354346 in PTGER4 
were related to susceptibility of AS in Europeans and East Asians, respectively (International 
Genetics of Ankylosing Spondylitis Consortium (IGAS) et al., 2013). In addition, 
rs76523431 in PTGER4 was also suggested as a risk factor of rheumatoid arthritis 
(Rodriguez-Rodriguez et al., 2015). PTGER4 gene polymorphisms (rs7720838, rs1494558) 
were associated with allergy and asthma (Kurz et al., 2006; Hinds et al., 2013), while 
rs4613763 was suggested as a psoriasis susceptible locus (Tsoi et al., 2015). Furthermore, 
epigenetic changes of the PTGER4 gene enhancer in Th17 cells were also found to be 
associated with human autoimmune diseases such as MS, CD and allergy (Farh et al., 2015). 
Consistent with these GWAS findings, expression of PGE2 signalling pathway genes 
(including both PGE2 synthases and receptors) was found positively correlated with IL-
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23/Th17 signature genes as well as disease severity in biopsy samples of human inflamed 
tissues with various chronic inflammatory conditions such as MS, CD, psoriasis and atopic 
dermatitis (Lee et al., 2018; Robb et al., 2018; and unpublished observations). Collectively, 
these genetic and epigenetic studies revealed conserved associations of variants in the PGE2-
EP4 signalling pathway with various IL-23/Th17-dependent human chronic autoimmune 
diseases. 
 
1.2. PGE2-EP4 signalling in generation of IL-22-producing Th22 cells and Th22-mediated 
inflammation  
IL-22 that is produced by Th17 cells and other activated T cells such as Th22 cells is 
involved in inflammation of the skin, gut, liver, lung as well as infections and tissue 
remodeling (Sabat et al., 2014). Robb et al recently reported that PGE2 promotes IL-22 
production from T cells under the Th22-skewing conditions with IL-23 or IL-6 or both and 
this effect was mediated by the EP2/EP4-cAMP-PKA pathway through induction of aryl 
hydrocarbon receptor. Consistently, T cell-specific EP4 deficiency as well as COX inhibition 
reduced hapten (e.g. dinitro-fluorobenzene)-induced generation of IL-22
+
 T cells in vivo and 
attenuated chronic allergic contact dermatitis induced by repeated oxazolone challenge (Robb 
et al., 2018). Interestingly, genes related to PGE2 and IL-22 pathways were coordinately 
upregulated in lesional skin from human atopic dermatitis, and their expression in inflamed 
skin was also down-regulated after receiving corticosteroid or ultraviolet B treatments (Robb 
et al., 2018). These results suggest a crucial role for PGE2-IL-6/IL-23 crosstalk in generation 
of IL-22
+
 T cells and promoting T cell-mediated chronic inflammatory skin disease. 
 
1.3. PG signalling in Th2 cell-mediated allergic inflammation 
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Unlike Th1 and Th17 cell differentiation, DCs do not produce IL-4, the key cytokine for Th2 
differentiation, and differentiation of Th2 cells are induced by direct and indirect interaction 
of T cells with DCs, basophils, ILCs, epithelial cells and maturing Th2 cells themselves and 
factors released from these cells such as epithelial cell-produced cytokines, IL-25, IL-33 and 
TSLP and IL-4 produced by maturing Th2 cells and basophils (Walker and McKenzie, 2017). 
Th2 cells provide protective type 2 immune responses against parasite but also underpin 
chronic, allergic inflammatory diseases such as atopic dermatitis and asthma. In contrast to 
PGE2-facilitated Th1 differentiation and Th17 expansion, most PGs appears to suppress Th2 
differentiation. Nakajima et al found that IP stimulation concentration-dependently facilitates 
Th1 differentiation under the Th1 skewing conditions, but suppresses Th2 differentiation of 
BALB/c CD4
+
 T cells under the Th2-skewing condition. This IP-mediated pathway appears 
to suppress Th2 cell differentiation in vivo (Nakajima et al. 2010). Indeed, mice deficient in 
IP exhibited significantly higher serum IgE levels compared to wild type mice and showed 
significantly enhanced allergic inflammation of the lung in ovalbumin (OVA)-induced 
allergic asthma model (Nagao et al., 2003). Zhou et al confirmed these phenotypes of IP-
deficient mice and further revealed that these phenotypes are caused by IP-deficiency in a 
STAT-6-independent manner (Zhou et al., 2016b). Similar to IP-deficient mice, EP2-
deficient mice also exaggerated OVA-induced airway inflammation accompanied with 
increased IL-13 production with higher serum IgE levels, and the administration of 
misoprostol during the sensitization oppositely suppressed the IgE production and attenuated 
the inflammatory response (Zasłona et al., 2014). The same phenotype, i.e. exaggerated 
allergic inflammation with higher IgE, was also found in mice deficient in either COX-1 or 
COX-2 subjected to the OVA model.  These results suggest that the PGE2-EP2 axis and the 
PGI2-IP axis function as an endogenous brake on allergen sensitization of T cells, though the 
detailed mechanism remains unknown.  
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In addition to these analyses on the role of PGs in allergen sensitization, several studies have 
also revealed PG actions in effector phase of Th2 cell-driven allergic inflammation. The best-
analyzed PG in this phase is PGD2, which is abundantly produced by mast cells activated by 
allergens. PGD2 acts on DP1 and DP2 receptors, and both PGD receptors regulate allergic 
inflammation positively. Th2 cells highly express DP2, and PGD2 binding to DP2 on Th2 
cells stimulates their migration to inflamed sites and enhances type 2 cytokine production 
(Hirai et al., 2001; He et al., 2010). Pharmacological inhibition of DP2 using small molecule 
inhibitors has been tested in randomized clinical trials for their efficacy to treat asthma and 
exhibited significant improvements in lung function and inflammation (Walker and 
McKenzie, 2017). It is unclear whether they targeted Th2 cells only, because eosinophils, 
mast cells and type 2 ILCs (ILC2s) also express DP2. Screening studies using mice deficient 
in each PG receptor suggest an important role of another PGD receptor, DP1, in allergic 
asthma (Matsuoka et al., 2000). Deficiency of DP1 did not affect serum IgE levels in OVA-
challenged mice but reduced production of antigen-specific Th2 cytokines, accumulation of T 
cells and eosinophils, epithelial mucus secretion and airway hypersensitivity in the sensitized 
lung (Matsuoka et al., 2000). This phenotype in DP1-KO mice was mimicked by 
administration of DP1-selective antagonist, S-5751, to sensitized wild mice (Arimura et al., 
2001). Interestingly, expression of DP1 in the lung was increased after OVA challenge and 
the immune-reactivity was localized in the airway epithelial cells, suggesting that PGD2 may 
activate epithelial cells by binding to their DP1 receptor (Arimura et al., 2001). Opposite to 
these PGD2 actions, PGE2 appears to exert suppressive actions also in the effector phase of 
type 2 allergic inflammation through various receptors. Kunikata et al found that, compared 
with WT mice, EP3-deficient mice had increased type 2 cytokine production and T cell 
infiltration in the lung and augmented airway inflammation induced by ovalbumin (OVA) 
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(Kunikata et al., 2005). They further found that OVA challenge induced expression of a 
variety of genes related to allergic inflammation and tissue remodeling including the 
chemokine thymus and activation-regulated chemokine (TARC, also known as CCL17) and 
eotaxin, in the lung, and the EP3 agonist treatment suppressed this induction and the above 
asthmatic symptoms. Intriguingly, EP3 and TARC are both apparently expressed in the 
airway epithelium and the agonist administration suppressed the TARC expression (Kunikata 
et al., 2005), suggesting that PGE2-EP3 signalling inhibits allergic inflammation by 
suppressing the allergen-induced gene expression in the epithelium. Because DP1 is also 
expressed in the airway epithelium and exerts opposite actions to EP3, and EP3 and DP1 are 
coupled oppositely to adenylate cyclase via Gi and Gs, respectively, these results suggest that 
the airway epithelium is the action site of these PGs. In addition to Th2 cells, T cells 
expressing IL-9 named Th9 cells contribute to allergic inflammation by promoting mast cell 
expansion and IL-13 production. Li et al examined the role of PGs in Th9 generation by 
subjecting COX-1- and COX-2-deficient mice to the OVA model, and found enhanced 
generation of Th9 cells in the absence of COX-2. They then found that PGD2 and PGE2 
suppressed in vitro Th9 differentiation induced by TGF- and IL-4 through cAMP pathway, 
which was due to down-regulation of IL-17RB that was responsible for Th9 expansion 
induced by IL-25 endogenously produced in T cells during the Th9 differentiation (Li et al., 
2013). These studies collectively suggest that PGs have diverse effects on Th2-cell mediated 
type 2 immune responses and allergic inflammation, which is likely determined by the 
balance of different PGs during antigen sensitization and challenge. In addition to the above 
studies focused on allergic inflammation, Birrell et al examined the EP receptors mediating 
the anti-inflammatory and bronchodilator activities of exogenously added PGE2 in the lung in 
various lung disease models and found that EP4 agonists can control airway inflammation 
induced by endotoxin, OVA or cigarette smoke (Birrell et al. 2015).   
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1.4. PG signalling in inflammation mediated by ILCs 
Innate lymphoid cells (ILCs) are recently identified new types of innate immune cells with 
transcriptional, functional and phenotypic similarities to Th subsets but without lymphocyte 
lineage markers and antigen receptors. ILCs therefore respond not to antigens but to 
environmental factors such as cytokines and lipid mediators. Similar to Th subsets, ILCs are 
classified into three subsets, ILC1, ILC2 and ILC3, according to their cytokine production 
and master transcription factors; ILC1s produce IFN-γ in response to IL-12, ILC2s produce 
type 2 cytokines such as IL-5 and IL-13 in response to epithelial cytokines (alarmins), IL-33, 
IL-25 and TSLP, and ILC3s produce IL-22 and/or IL-17 in response to IL-23 and IL-1β. 
(Klose and Artis, 2016). As indicated by the above property, ILC2s mediate type 2 immune 
responses and allergic diseases like Th2 cells in response to alarmins, various cytokines and 
lipid mediators. The most well-studied PG affecting ILC2 responses is PGD2. Like Th2 cells, 
human ILC2 cells highly express PGD receptor DP2 (Mjösberg et al., 2011). Engagement of 
DP2 by PGD2 enhanced ILC2 migration and induced expression not only of genes for type 2 
cytokines such as IL-4, IL-5 and IL-13 but also genes for IL-33 and Il-25 receptor subunits, 
ST2 and IL-17RA, respectively, thus amplifying IL-33 and IL-25 signalling pathways for 
production of type 2 cytokines and promoting allergic inflammation in skin and lung (Chang 
et al., 2014; Xue et al., 2014). Eastman et al reported that ILC2 cells were specifically 
recruited to nasal mucosa in patients with aspirin-exacerbated respiratory disease during 
aspirin challenge with paradoxical increase in urinary PGD2 metabolite, 11-PGF2 (Eastman 
et al., 2017). This study indicates that PGD2 may have critical roles in recruiting and 
activating ILC2s through DP2 in aspirin-exacerbated respiratory disease. PGD2 similarly 
induces ILC2 chemotaxis in a DP2-dependent manner in mice. Wild type mice infected with 
helminth exhibited pulmonary ILC2 accumulation and type 2 inflammation, which was 
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significantly reduced by the DP2 deficiency and administration of a DP2 antagonist (Wojno 
et al., 2015), demonstrating that PGD2-DP2 axis is indeed involved in ILC2 recruitment in 
vivo. On the contrary to PGD2, PGE2 suppresses upregulation of GATA3 and CD25 (i.e., IL-
2 receptor- induced by IL-33/IL-25/TSLP in human ILC2 cells, and inhibits ILC2 
proliferation and expression of type 2 cytokines such as IL-5 and IL-13 through EP2 and EP4 
(Maric et al., 2017). In addition, PGI2 also inhibited IL-33-stimulated ILC2 activation and 
type 2 cytokine production in vitro. Administration of cicaprost, a synthetic IP agonist, 
suppressed ILC2 response and lung inflammation induced by a fungal aeroallergen while IP-
deficiency augmented this ILC2-dependent in vivo allergic immune responses, suggesting a 
critical role for endogenous PGI2-IP signalling in control of ILC2-mediated allergic 
inflammation (Zhou et al., 2016a).  
 
As for the role of PGs in ILC3, Duffin et al recently reported that PGE2 promoted IL-23-
induced ILC3 activation and IL-22 production in vitro, and this was mediated by EP2/EP4-
cAMP-PKA signalling (Duffin et al., 2016). Given that IL-22-producing ILC3 cells play 
important roles in mucosal homeostasis and control of acute epithelial damage (Klose and 
Artis, 2016), they examined the significance of this pathway in LPS-induced systemic 
inflammation. They found that COX inhibition with indomethacin markedly exacerbated 
LPS-induced systemic inflammation, which was caused by enhanced gut bacterial 
translocation due to reduced number of ILC3 cells and IL-22 production in the intestine, and 
that all of these phenotypes could be prevented by administration of an EP4 selective agonist 
or exogenous IL-22. They further showed that EP4 deletion in ILCs led to reduction of IL-22 
production and augmented systemic inflammation as exemplified by enhanced TNF-α 
production. Moreover, PGE2 also enhanced IL-22 production from IL-23/IL-1β-stimulated 
human ILC3s. These results together suggest that PGE2-EP4 signalling directly acts on ILC3s 
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to potentiate their homeostasis and function in the intestine and promoting its barrier function 
to prevent systemic and intestinal inflammation (Duffin et al., 2016). In addition to such 
cytoprotective action, IL-22-producing ILC3 cells sustain colon cancer in a colitis-associated 
cancer model of 129SvEv.Rag
-/-
 mice treated with Helicobacter hepaticus and azoxymethane 
(Kirchberger et al., 2013), and some ILC3s also produce pro-inflammatory cytokines (e.g., 
IL-17A, IFN-γ and GM-CSF) in response to IL-23 and other cytokines such as IL-1 and IL-
12 (Klose and Artis, 2016), and contribute to intestinal inflammation (Buonocore et al., 2010). 
Whether PGE2 or other PGs can also promote such mucosal inflammation through 
stimulating the pro-inflammatory ILC3s similarly to pathogenic Th17 cells by interacting 
with IL-23 and/or IL-1β is not known.  
 
1.5 PG signalling in regulation of B cell responses 
Previously PGE2 was shown to be involved in modulation of immunoglobulin class switching 
to IgG1 and IgE synthesis in vitro through EP2/EP4-cAMP signalling (Harris et al., 2002). 
Consistent with these findings, Gao et al. found that PGE2 enhances IL-4-induced STAT6 
activation in an EP2 dependent manner to prompt IgE switching, and that in OVA-induced 
asthma model, mice with EP2 deficiency exhibited markedly attenuated IgE antibody 
responses and airway inflammation (Gao et al., 2016). Furthermore, also consistent with the 
earlier findings on PGE2-mediated inhibition of B cell activation (Roper et al., 1994), Murin 
et al found that PGE2 suppresses B cell receptor-mediated proliferation of B cell lymphomas 
through EP4 and that gene knockdown of Ptger4 (encoding EP4) in B cell lymphoma 
markedly accelerates tumor spread in mice, while PTGER4 overexpression yields significant 
protection (Murn et al., 2008). Because EP4 expression is down-regulated in the lymphoma, 
the authors suggested tumor-suppressor role of EP4. Prijatelj et al suggested that PGE2-EP4 
signalling-mediated elevation of cAMP and inactivation of NF-B by EP4 may be involved 
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in the inhibition of B cell proliferation (Prijatelj et al., 2012). In germinal center (GC), B cells 
are selected through interaction with follicular dendritic cells bearing immune complexes in 
an antigen affinity-dependent manner in the so-called affinity maturation process, and IL-21 
produced by follicular helper T cells stimulates this process. Magari et al constructed co-
culture of FL-YB follicular dendritic cells and B cells and found that FL-YB cells produced 
PGE2, which, combined with IL-21, acted on EP4 and induced B cell death by up-regulation 
of proapoptotic protein Bim and Foxo1 (Magari et al., 2011). Since treatment with 
indomethacin and EP4 antagonist ONO-AE3-208 significantly decreased the number of 
apoptotic GC B cells, these authors indicated that the IL-21-PGE2 crosstalk physiologically 
regulates B cell death in GC B cell selection. In addition to these PG actions on B cell fate in 
the periphery, mice deficient in COX1 had the arrest of early B-cell development from pro-B 
to pre-B stage and caused systematic reduction in total B cells (Yang et al., 2014). 
Mechanistic studies revealed that COX-1-derived TXA2 regulated JAK3/STAT5 signalling 
through binding to TP. Treatment of COX1-deficient mice with a TP agonist rescued the 
defective B cell development and JAK3/STAT5 signalling activity (Yang et al., 2014).  
 
2. PG-cytokine crosstalk in myeloid and stromal cell-mediated chronic inflammation 
Chronic inflammation is characterized by persistent infiltration with mononuclear cells 
including macrophages, lymphocytes and plasma cells in most cases, and, in some cases, 
polymorphonuclear leukocytes (PMNs), and consequent tissue destruction largely by the 
products of these infiltrating inflammatory cells (Kumar et al., 2018). Tissue remodeling such 
as angiogenesis and fibrosis is also simultaneously seen in chronic inflammation. Substantial 





This article is protected by copyright. All rights reserved. 
 
2.1. PG-cytokine crosstalk in macrophages and neutrophils 
Macrophage is one of the main cell sources for PGs in inflammation and the produced PGs 
act back on macrophages and amplify their function. For example, while LPS induced 
expression of COX2, IL-1β and IL-6 in cultured macrophages, this induction was attenuated 
by celecoxib, a COX2 inhibitor, or RQ-00015986, an EP4 antagonist, suggesting the positive 
feedback loop for LPS-activated endogenous PGE2-EP4 signalling in macrophages (Oshima 
et al., 2011). Such PG-mediated positive feedback loop has been shown in various models of 
chronic inflammation. Intracranial aneurysm (IA) is chronic inflammation of the cerebral 
artery histologically characterized by degenerative changes of arterial walls and inflammatory 
cell infiltration consisting mainly of macrophages (Chyatte et al., 1999). Aoki et al identified 
the PGE2-EP2-NF-κB signalling cascade in macrophages infiltrating the arterial wall as a 
factor sustaining the IA pathogenesis and making the inflammation chronic (Aoki et al. 2017). 
They found that PGE2 activates NF-κB synergistically with TNF-α via EP2 in macrophages 
in vitro to induce pro-inflammatory genes including COX2 and macrophage chemokine 
CCL2 (also called MCP-1), and that CCL2 mRNA is also stabilised by this pathway. 
Consistent with these in vitro findings, mice with macrophage-specific EP2 deletion or with 
transgenic expression of an IB mutant that restricts NF-κB activation showed reduced IA 
incidence with fewer infiltrated macrophages (Aoki et al. 2017). Similarly, administration of 
an EP2 antagonist in rat model of IA reduced macrophage infiltration and suppressed IA 
formation and progression (Aoki et al., 2011; Aoki et al., 2017). The authors suggest that 
PGE2-EP2 signalling not only amplifies inflammation by making a positive feedback loop 
involving NF-κB and COX-2 but also amplifies macrophage recruitment by increasing and 
sustaining CCL2 expression at the inflamed site by this loop, contributing to pathogenesis of 
IA (Figure 4A) (Aoki et al., 2017). Indeed, infiltration of macrophage expressing COX-2 and 
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EP2 was found in clinical samples of human IA (Aoki et al., 2017). On the other hand, 
Kumei et al used diet-induced nonalcoholic steatohepatitis model and found that IP 
deficiency accelerates disease progression by augmented histological derangement including 
cell infiltration accompanied by increased expression of MCP-1 (also called CCL2) and TNF-
. Such disease progression in WT mice is significantly suppressed by administration of an 
IP agonist, beraprost (Kumei et al., 2018). These results indicate that PGI2-IP signalling 
down-regulates MCP-1 and TNF- and suppresses inflammation, an opposite action to 
PGE2-EP2 signalling described above, and suggest that similar PG signalling exert different 
actions in different context. Similarly, TXA2 can also promote MCP-1 and its receptor CCR2 
expression in macrophages. In the carbon tetrachloride-induced liver injury and repair model, 





macrophages and hepatic expression of MCP-1, CCR2, IL-6, TNF-, and hepatocyte growth 
factor, leading to impaired liver regeneration (Minamino et al., 2012).  
 
Other examples of cytokine-PG interaction in macrophages have been reported in 
inflammation associated with bacterial and viral infection (Figure 4B). Mayer-Barber et al 
found that Mycobacterium tuberculosis infection induced IL-1 and IL-1 production, which 
in turn induced PGE2 production by macrophages and enhanced their antimicrobial activity 
(Mayer-Barber et al. 2014). Type 1 IFNs are known to antagonize the IL-1 receptor (IL-1R) 
pathway during mycobacterium infection and subvert anti-tuberculosis host defence. They 
found that the IL-1R-PGE2 pathway inhibits type 1 IFN synthesis in macrophages, and 
counter-regulates their actions. Therefore, blocking IL-1R or COX2 signalling or enhancing 
IFN signalling caused uncontrolled M. tuberculosis infection, leading to mortality and 
necrotic lung inflammation, but this could be prevented by administration of exogenous PGE2 
(Mayer-Barber et al., 2014). This study provided a novel mechanism for how the IL-1R-
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PGE2-IFN interaction in macrophages determines outcomes of bacterial infection and 
suggests potential therapeutic strategies for tuberculosis by targeting the lipid-cytokine 
crosstalk. However, the PGE2-IFN interaction can also yield opposite outcome in viral 
infection. Influenza virus infection evoked PGE2 production, which inhibits type 1 IFN 
production and suppresses apoptosis in macrophages through EP2 and EP4, leading to 
augmented viral infection and dissemination (Coulombe et al., 2014). Since macrophage 
apoptosis produces apoptotic vesicle containing viral antigens and type 1 IFNs can enhance 
antigen cross-presentation, PGE2-mediated suppression of apoptosis and inhibition of type 1 
IFNs also suppressed macrophage antigen presentation and subsequent T cell immunity. In 
influenza virus infection, therefore, blocking COX2, mPGES1 or EP2/EP4 improves survival 
against lethal virus infection (Coulombe et al., 2014). 
 
Peters-Golden and collaborators examined signalling mechanisms downstream of cAMP in 
PGE2-mediated inhibition of alveolar macrophages. They found that, in alveolar macrophages, 
inhibiting the generation of proinflammatory mediators (such as TNF, MIP-1 and LTB4) 
and increasing in IL-10 and IL-6 production are mediated by PKA, and suppressing FcR-
mediated phagocytosis is mediated by Epac, while inhibition of bacterial killing by reactive 
oxygen species is mediated by both PKA and Epac (Aronoff et al., 2005). They then showed 
that the PGE2-EP2-PKA/Epac signalling interferes translocation of p47phox to phagosomal 
membrane and thus limits bacterial killing by reducing generation of reactive oxygen species 
(Serezani et al., 2007). Wall et al. further found that differential effects of cAMP on the 
production of pro- and anti-inflammatory cytokines were mediated by different classes of A 
kinase-anchoring proteins (AKAPs) that complex with PKA and determine cellular 
localization of PKA specific to each action. Specifically, they showed that cAMP-dependent 
suppression of LPS-induced expression of TNF- is carried out by the AKAP95-PKA 
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complex that targets PKA to NF-B p105 (Wall et al., 2009). Formation of various targeting 
multimer complexes may help us to understand context-and cell-dependent pro-and anti-
inflammatory actions of PGE2-EP2/EP4 signalling. Peter-Golden’s group also showed that 
PGE2 inhibits macrophage maturation. Macrophages deficient in EP2 exhibited enhanced in 
vitro maturation and EP2
-/-




 cells and 
greater expression of macrophage colony-stimulating factor receptor. This inhibitory effect 
was also through the EP2-PKA signalling pathway (Zaslona et al., 2012).  
 
Neutrophils have been traditionally regarded innate immune cells that combat invaders in 
acute infection but with restricted pro-inflammatory functions. Recent studies, however, 
indicate that neutrophils are capable of a vast array of pro-inflammatory functions and 
contribute also to chronic inflammation (Kolaczkowska and Kubes, 2013). Indeed, in 
inflammatory bowel diseases, neutrophils extensively infiltrate the mucosa and crypts of the 
intestine, which correlates with mucosal injury and patient symptoms (Brazil et al., 2013). 
Recent studies have shown that PGs are involved in various proinflammatory functions of 
neutrophils and modulate inflammation. Ma et al found extensive neutrophil infiltration in 
association of tumour development in the colon in the azoxymethane (AOM)/dextran sulfate 
sodium (DSS)-induced colitis-associated colorectal cancer model, and reported that PGE2 
was involved in this sustained neutrophil accumulation. (Ma et al., 2015) Infiltrating 
neutrophils highly expressed EP2 and that EP2 agonist and TNF-α synergistically induced 
expression of various inflammation-related genes in vitro in primary cultured neutrophils 
including COX-2, a cytokine, IL-6 and a chemokine, CXCL1, through NF-B. EP2 
deficiency or EP2 antagonism abolished neutrophil infiltration, suppressed expression of 
inflammatory genes including CXCL1, and decreased the number of colon tumours (Ma et al., 
2015). These findings are consistent with the preceding study by Katoh et al who used the 
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same model and found that inflammatory cells accumulate in the colon in a manner 
dependent on CXCR2, a receptor for CXCL1, though they suggested these cells as 
neutrophilic myeloid-derived suppressor cells (Katoh et al. 2013). As neutrophils produce 
PGE2 via COX-2, these results together indicate that neutrophils self-amplify their 
recruitment through the TNF-α-primed PGE2-EP2-NF-B-CXCL1 pathway and recruited 
neutrophils amplify inflammation for tumour development (Figure 4C). These works have 
thus provided new mechanistic interpretation for epidemiological findings showing that 
NSAIDs prevented colorectal cancer development and progression (Thun et al., 1991; 
Rothwell et al., 2010) and experimental work showing that genetic deletion of COX2, 
mPGES1 or EP2 reduced the number and size of adenomas in AOM/DSS- or APC
Min/+
-
induced CRC models (Oshima et al., 1996; Nakanishi et al., 2008; Sonoshita et al., 2001). 
The involvement of PG in the above scenario may not be limited to PGE2. Wallace et al 
found that PGF2-FP signalling is elevated in endometrial adenocarcinoma cells and up-
regulates tumorigenic and angiogenic genes including COX-2, FGF2 and VEGF (Wallace et 
al., 2009). They further showed that CXCL1 and CXCR2 expression was elevated in the 
cancer tissue and that PGF2-FP signalling promotes CXCL1 expression on endometrial 
adenocarcinoma cells and attracts CXCR2-expressing neutrophils (Wallace et al., 2009). 
Neutrophil-produced TXA2 is recently reported to modulate neutrophil-dependent control of 
lymphocyte egress after adjuvant administration during immunisation and the neutrophil 
spread outside the draining lymph nodes (Yang and Unanue, 2013).  
 
The above described pro-inflammatory actions of PGE2-EP2 signalling on neutrophils appear 
contradictory to the classic findings that PGE2 inhibits human neutrophil function and 
migration through EP2 (Wheeldon and Vardey, 1993; Armstrong, 1995) and the recent 
findings that PGE2-EP4 signalling inhibits neutrophil migration in vivo (Mizuno et al., 2014). 
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There is also a study reporting that during acute mucosal infection with Toxoplasma gondii, 
intestinal monocyte-produced PGE2 controls neutrophil activation to commensal bacteria, 
limiting mucosal damage during acute intestinal infection (Grainger et al., 2013). This 
apparent contradiction suggests that whether PGE2 exerts pro- or anti-inflammatory action 
depends on the context of each pathology and experimental setting such as whether PGE2 acts 
alone or with cytokines and acts in which cellular background. In contrast to PGE2 and 
PGF2, PGD2-DP2 signalling is implicated as another PG signalling oppositely controlling 
neutrophil recruitment. DP2 deficient mice were more resistant to caecal ligation and 
puncture-induced sepsis model by showing enhanced CXCR2-positive neutrophil 
accumulation in the infections focus, reduced pro-inflammatory cytokine production and 
improved bacterial clearance (Ishii et al., 2012). While this finding suggests that PGD2-DP2 
signalling negatively regulates neutrophil recruitment, its mechanism remains unknown. 
 
In inflammatory conditions, neutrophils release intracellular structures composing of 
chromatin DNA, histones and granular proteins, make a net-like structure. This structure, i.e. 
neutrophil extracellular trap (NET), functions to trap and clear bacteria. NET formation also 
occurs during various chronic inflammatory diseases (Kolaczkowska and Kubes, 2013). 
PGE2 inhibited NET formation in isolated neutrophils induced by phorbol 12-myristate 13-
acetate or rapamycin through EP2/EP4-cAMP signalling (Domingo-Gonzalez et al., 2016; 
Shishikura et al., 2016), although how much this mechanism operates in vivo remains 
unknown. 
 
2.2. PG-cytokine crosstalk in inflammatory stroma 
The stroma of chronic inflammation is not only the site where active inflammation, tissue 
degradation and remodelling occur but also contributes itself to inflammation with its cell 
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components that actively evoke and perpetuate inflammatory responses as exemplified by 
fibroblast-like synoviocytes (FLSs) in rheumatoid arthritis (Bartok and Firestein, 2010) and 
tumour-associated fibroblasts (TAFs) in many cancers (Kalluri, 2016). Involvement of PGs in 
this active process of stroma has also been reported. For example, Honda et al. used the 
collagen-induced arthritis, a model of RA, and found that IP deficiency and EP2/EP4 
deficiency significantly reduced the severity of arthritis assessed by synovial cell 
proliferation, inflammatory cell infiltration and joint destruction, which were accompanied by 
significant reduction in the content of IL-6 in arthritic paws (Honda et al., 2006). They further 
used cultured synovial fibroblasts and found PGI2 synergized with IL-1β to amplify IL-6 
production, which was reduced by a COX inhibitor, indomethacin. Microarray analysis 
revealed that, in addition to IL-6, PGI2-IP signalling amplified expression of genes related to 
inflammation (e.g. IL-11, CXCL7), cell proliferation (e.g. fibroblast growth factor and 
vascular and endothelial growth factor), tissue remodelling (e.g. RANKL, ADAM8) as well 
as IL-1 receptor (IL1R1) itself. Given that PGI2 alone did not induce expression of these 
genes, these findings indicate that PGI2-IP signalling functions as an amplifier of IL-1β 
signalling by expression of its receptor in synovial fibroblasts to significantly augment 
inflammation (Honda et al., 2006). Consistently, Kunisch et al found that TNF-α stimulation 
drove COX-2 expression and production of PGE2, which acts back on FLSs to induce IL-6 
production via EP2, by using FLSs from RA patients (Kunisch et al., 2009). Paulissen et al 
found that co-culture of primary human Th17 cells with FLSs from RA patients led to more 
IL-17A production, and this autocrine IL-17 production as well as induction of IL-6, IL-8 and 
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Similar to FLSs in RA, TAFs exert pleiotropic functions in tumour microenvironment for 
progression of cancer (Kalluri, 2016). In an aforementioned work on colitis-associated cancer, 
Ma et al used bone marrow chimera and found that not only EP2-expressing neutrophils but 
also EP2-expressing TAFs made significant contribution to tumour progression. They found 
that the positive feedback loop of PGE2-EP2-NF-B-COX-2 signalling also functioned in 
TAFs and in synergy with TNF- to amplify the expression of proinflammatory genes such 
as IL-6, tumour promoting genes such as various WNT molecules, and genes for tissue 
remodelling such as BDNF, MMP12 and osteopontin (Ma et al. 2015). These studies suggest 
that fibroblasts play an active role in chronic inflammation and that PG signalling contribute 
to their function by synergistic interaction with cytokines (Figure 4D). 
 
Fibrosis and angiogenesis are ultimate hallmarks of chronic inflammation. PGs also play 
critical roles in these processes. In the bleomycin-induced pulmonary fibrosis model, Oga et 
al found that FP deficiency attenuated the fibrosis (i.e., reduced collagen synthesis) in this 
model, which was independent of TGF-β and without influence on inflammatory responses 
(Oga et al., 2009). Consistently, PGF2 enhanced collagen synthesis in lung fibroblasts in 
vitro in an additive way to TGF-β, indicating that PGF2-FP signalling exerts a pro-fibrotic 
action on its own in fibrosis (Oga et al., 2009). In contrast, other PGs were reported to be 
anti-fibrotic. For example, mice without IP signalling had augmented bleomycin-induced 
pulmonary fibrosis (Lovgren et al., 2006). IP knockout mice developed cardiac fibrosis, 
which was suppressed completely by coincidental deletion of TP (Francois et al., 2005), 
suggesting IP and TP signalling pathways antagonize in cardiac fibrosis. PGE2-EP4 
signalling has been reported to prevent tubulointerstitial fibrosis in the kidney of mice 
subjected to unilateral ureteral obstruction (Nakagawa et al., 2012). These studies indicate 
critical roles of PGs in activation and function of fibroblasts, but whether these effects can be 
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modulated by the immune system and cytokines remains for further studies. Given that both 
type 2 cytokines (e.g. IL-4/IL-5/IL-13)-producing Th2/ILC2 cells and IL-17/IL-22-
expressing Th17/ILC3 cells have been demonstrated to regulate fibrosis (Barron and Wynn, 
2011; Hams et al., 2015) and that PGs play essential roles in regulation of immune responses 
as described above, it will be interesting to examine whether PGs control fibrosis through the 
immune system. Likewise, PG signalling functions in angiogenesiss. Amano et al implanted a 
Matrigel sponge or tumour cells in mice and found PGE2-EP3 signalling facilitates 
angiogenesis associated with chronic inflammation in the sponge and tumors (Amano et al., 
2003). Bone marrow transfer experiment indicates that EP3-bearing bone marrow-derived 





 cells to the site of angiogenesis (Ogawa et al., 2009). 
 
3. Conclusion 
As reviewed here, substantial evidence derived from in vitro and in vivo animal model 
experiments now suggest that PGs are significantly involved in chronic inflammation by 
regulating both innate and adaptive immune cells, and gene signature analysis of clinical 
samples as well as GWAS of patients appears to support these experimental findings. In the 
processes of chronic inflammation, PGs crosstalk intimately with cytokines in various ways. 
One is to induce or enhance expression of receptor(s) for the involved cytokines, which is 
seen in PGE2-EP2/EP4 signalling-mediated IL-12R2 and IFNR1 induction in Th1 cells, IL-
23R induction in Th17 cells, PGD2-DP2 signalling-mediated ST2 and IL-17RA induction in 
ILC2 cells, and PGI2-IP signalling-mediated IL-1R1 induction in synoviocytes. Another is to 
collaborate with cytokine, particularly, TNF-, to enhance NF-B activation and induction of 
COX-2 to self-amplify this signalling, which is seen in inflammation driven by macrophages 
such as intracranial aneurysm and neutrophil-driven inflammation in colitis-associated cancer. 
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It may not be overstated that this COX-2 mediated amplification mechanism operates in 
various chronic inflammatory diseases that exhibit high expression of COX-2 together with 
activated NF-B. It is clearly noted, however, that actions of PGs and their signalling in 
chronic inflammation are strictly dependent on the context, e.g. the types of inflammation, 
cytokines, cells and so on, the timing of disease process, and the sites of inflammation, which 
cannot easily generalize as seen in acute inflammation. For example, while PGE2-EP2/EP4 
signalling facilitates Th1/Th17-mediated immune inflammation and sustains macrophage- or 
neutrophil-driven inflammation, the same signalling pathway dampens Th2-mediated allergic 
inflammation. The same is true for PGI2-IP signalling. Although PGD2-DP2 signalling 
recruits Th2 cells, eosinophils and ILC2 cells, this signalling appears to function differently 
in neutrophil recruitment in caecal puncture model. It should be mentioned therefore that 
although we believe in great potential of PG receptor type-selective agonists and antagonists, 
application of these drugs should be carefully thought out by analysing clinical and 
pathological context of each disease in the background of experimental studies. One 
successful example among this line may be application of DP2 antagonists to asthmatic 
patients (Kuna et al., 2016; Erpenbeck et al., 2016). As seen there, experimental studies to 
date have now accumulated enough amount of information as the base and framework for 
identifying clinical indication. Given the adverse effects of traditional NSAIDs, it is the time 
to examine the potential of such receptor-selective molecules to manipulate chronic 
inflammatory diseases. In this respect, one aspect of PG studies we cannot cover in this 
review due to the space limit is the PG actions in immune evasion in cancer, which is 
currently an active and expanding area of research. Interested readers are recommended to 









Nomenclature of targets and ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018) and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c). 
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Figure 1. Prostaglandin (PG) biosynthesis, receptors and signalling pathways.  
(A) Arachidonic acid is metabolised by COX, either COX1 or COX2, to PGH2, which is then 
converted to each PG, PGD2, PGE2, PGF2, PGI2 or TXA2, by respective synthases. 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COXs and suppresses PG 
biosynthesis. Each PG acts on its cognate receptor to exert its actions. PGD2 acts on PGD 
receptors, DP1 and DP2 (formerly designated as CRTH2); PGE2 acts on four subtypes of 
PGE receptors, EP1, EP2, EP3 and EP4; PGF2 acts on PGF receptor, FP; PGI2 acts on 
PGI receptor, IP; TXA2 acts on TXA receptor, TP 
(B) All of the nine PG receptors are G protein-coupled receptors and exert their actions by 
modulating second messengers and intracellular signal transduction. Dependent on their 
downstream signalling pathways and structural similarity, they are classified into three 
groups. The relaxant group consists of DP1, EP2, EP4 and IP that are mainly coupled to 
elevation of intracellular cAMP levels and activate the cAMP-PKA-CREB pathway. The 
contractile group consists of EP1, FP and TP that are coupled to Ca
2+
 signalling and PKC 
activation. Both EP3 and DP2 are coupled to reduction in the levels of intracellular 
cAMP, and belong to inhibitory PG receptor group. However, while EP3 with other PG 
receptors constitutes the family of PG receptors, DP2 belongs to the chemo-attractant 
GPCR family.  In addition to these main downstream signalling pathways, each PG 
receptor also activates other signal transduction pathways. For example, EP2 and EP4 
activate the PI3K pathway and form a complex with β-arrestin to trans-activate the 
epidermal growth factor receptor; TP and EP3 activate the small G-protein Rho; IP 
activates the PKC and Ca
2+
 signalling, and DP2 activates the PI3K pathway. Furthermore, 
EP3 has various alternatively spliced variants in its carboxyl terminus, which can couple 
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Figure 2. PG-cytokine crosstalk in regulation of lymphocyte-mediated chronic 
inflammatory responses.  
(A) PGE2 and PGI2 crosstalk with IL-12 and IL-23 signalling pathways in Th1 and 
Th17/Th22 cells, respectively, and promote differentiation and expansion of these Th 
cell subsets both in vitro and in vivo, producing inflammatory cytokines such as IFN-, 
IL-17A, IL-17F, IL-22. These PG actions underlie Th1 and Th17 cell-mediated 
autoimmune inflammation in mouse models of multiple sclerosis (MS), rheumatoid 
arthritis (RA), inflammatory bowel disease (IBD), atopic dermatitis (AD) and psoriasis.  
(B) In response to IL-23 stimulation, type 3 innate lymphoid cells (ILC3) produce the 
cytokine IL-22, critical to epithelial homeostasis and modulation of inflammation. PGE2 
has been shown to augment IL-23-induced IL-22 production from ILC3s through the 
EP4-cAMP-PKA pathway, facilitating intestinal epithelial homeostasis and control of 
systemic inflammation.  
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(C) PGE2 and PGI2 inhibit antigen-dependent activation and cytokine (IL-4, IL-5, IL-13) 
production in Th2 cells and thus limit type 2 allergic inflammation. In contrast, PGD2 
promotes allergic inflammation through DP2-mediated Th2 cell migration. 
(D) Epithelial cytokines such as IL-25, IL-33 or thymic stromal lymphopoietin (TSLP) 
stimulate type 2 innate lymphoid cells (ILC2) to produce type 2 cytokines including IL-4, 
IL-5, IL-13, developing type 2 allergic immune diseases such as asthma and atopic 
dermatitis (AD). While PGD2 promotes type 2 allergic immune response through driving 
ILC2 cell migration via DP2, PGI2 and PGE2 inhibit allergic immune responses through 
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Figure 3. Molecular mechanisms for PGE2-cytokine crosstalk in facilitation of adaptive 
Th1 and Th17 cell responses. 
(A) PGE2 through EP2/EP4 receptors activates the cAMP-PKA-CREB/CRTC2 pathway that 
in turn drives expression of IL-12Rβ2 and IFN-γR1 and amplifies cytokine signalling, 
leading to facilitation of Th1 cell differentiation. Additionally, activation of PI3K by 
strengthened CD28 co-stimulation and that by EP2/EP4 receptors further supports Th1 
cell differentiation by antagonising cAMP/PKA-mediated suppression of TCR activation. 
(B) IL-23 induces COX2 expression and low levels of PGE2 production by activated Th17 
cells. T cell-intrinsic PGE2 then acts back on Th17 cells for induction of IL-23R (and 
possibly also IL-1R) through the positive feedback IL-23-PGE2-EP2/EP4-cAMP-PKA-
STAT3/CREB/NF-B-IL-23R loop, leading to generation of pathogenic Th17 cells by 
synergistic actions with IL-23 and/or IL-1. CREB and CRTC2 can also directly drive IL-
17A gene expression by binding to its promoter. 
(C) Activation of NF-κB induced by TLR or CD40 engagement on DCs induces early phase 
of IL-23p19 gene expression. NF-κB also induces DCs to express COX2 and PGE2, 
which then further amplifies NF-κB signalling for the IL-23p19 expression through the 
EP2/EP4-cAMP-PKA-CREB pathways. PGE2 can also induce IL-23p19 expression 
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Figure 4. Molecular mechanisms for PG-cytokine crosstalk in amplification of innate 
immune cell responses. 
(A) TNF- and LPS activate NF-κB in macrophages to express COX2 and PGE2, which acts 
back on macrophages via EP2 to further amplify NF-κB signalling for induction and 
stabilization of CCL2 mRNA, recruiting macrophages to inflamed sites and promoting 
chronic inflammation.  
(B) Mycobacterium tuberculosis (Mtb) infection induces IL-1 production that in turn drives 
PGE2 production by macrophages. PGE2 then suppresses macrophage production of type 
1 IFNs via EP2/EP4, leading to exacerbation of Mtb infection. Similarly, influenza A 
virus infection also activate macrophage production of PGE2, which then suppresses type 
1 IFNs to control virus replication. 
(C) TNF- activates NF-κB in neutrophils to express COX2 and PGE2, which acts back on 
neutrophils via EP2 to amplify NF-κB signalling for induction of CXCL1 and 
inflammatory cytokines, leading to recruitment of neutrophils to chronic inflammation 
sites and tumour growth, respectively. 
(D) TNF- and IL-1β activate NF-κB in stromal cells (e.g., fibroblasts) to express COX2 and 
produce PGs (e.g. PGE2 and PGI2). PGE2 and PGI2 acts back on stromal cells through 
EP2/EP4 and IP, respectively, to induce IL-6 (likely also IL-1β) production, supporting 
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activation of residential Th17 cells and leading to chronic inflammation such as 
rheumatoid arthritis and tumour progression. 
 
